doi:10.3969/j.issn.1004-583X.2022.05.015

Abstract

CLC Number:

R742.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.05.015

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I5/463

References 31

[1]	Lee JY, Yoon EJ, Kim YK, et al. Nonmotor and dopamine transporter change in REM sleep behavior disorder by olfactory impairment[J]. J Mov Disord, 2019, 12(2): 103-112.
[2]	Hayes MT. Parkinson’s disease and parkinsonism[J]. Am J Med, 2019, 132(7):802-807. doi: 10.1016/j.amjmed.2019.03.001 URL
[3]	Raza C, Anjum R, Shakeel N. Parkinson’s disease: Mechanisms, translational models and management strategies[J]. Life Sci, 2019, 226(2):77-90. doi: 10.1016/j.lfs.2019.03.057 URL
[4]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[5]	Kung MP, Stevenson DA, Plossl K, et al. (99m)Tc-TRODAT-1 SPECT-1:A novel technetium-99mcomplex as a dopamine transporter imaging agent[J]. Eur J Nucl Med, 1997, 24(4):372-380. doi: 10.1007/BF00881808 pmid: 9096087
[6]	Sharp ME, Duncan K, Foerde K, et al. Dopamine is associated with prioritization of reward-associated memories in Parkinson’s disease[J]. Brain, 2020, 143(8):2519-2531. doi: 10.1093/brain/awaa182 URL
[7]	Tripathi M, Kumar A, Bal C. Neuroimaging in parkinsonian disorders[J]. Neurol India, 2018, 66(5):S68-S78.
[8]	Ikeda K, Ebina J, Kawabe K, et al. Dopamine transporter imaging in parkinson disease: Progressive changes and therapeutic modification after anti-parkinsonian medications[J]. Intern Med, 2019, 58(12):1665-1672. doi: 10.2169/internalmedicine.2489-18 URL
[9]	Sun Y, Liu C, Chen Z, et al. A phase 2, open-label, multi-center study to evaluate the efficacy and safety of (99m)Tc-TRODAT-1 SPECT to detect Parkinson’s disease[J]. Ann Nucl Med, 2020, 34(1):31-37. doi: 10.1007/s12149-019-01412-2 pmid: 31646428
[10]	Kuten J, Linevitz A, Lerman H, et al. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study[J]. J Integr Neurosci, 2020, 19(3):489-494. doi: 10.31083/j.jin.2020.03.196 URL
[11]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[12]	Bor-Seng-Shu E, Pedroso JL, Felicio AC, et al. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: A cross-sectional study[J]. Parkinsonism Relat Disord, 2014, 20(5):477-481. doi: 10.1016/j.parkreldis.2014.01.015 URL
[13]	Arena JE, Urrutia L, Falasco G, et al. Correlation between (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in patients with Parkinson's disease: A pilot study[J]. Radiol Bras, 2021, 54(4):232-237. doi: 10.1590/0100-3984.2020.0087 URL
[14]	Mittal BR, Sood A, Shukla J, et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes[J]. Nucl Med Commun, 2018, 39(4):312-318. doi: 10.1097/MNM.0000000000000802 URL
[15]	Sasannezhad P, Juibary AG, Sadri K, et al. (99m)Tc-TRODAT-1 SPECT imaging in early and late onset Parkinson's disease[J]. Asia Ocean J Nucl Med Biol, 2017, 5(2):114-119. doi: 10.22038/aojnmb.2017.8844 pmid: 28660222
[16]	Huang WS, Lin SZ, Lin JC, et al. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging[J]. J Nucl Med, 2001, 42(9):1303-1308. pmid: 11535717
[17]	Fornari L, Da S, Muratt C, et al. Striatal dopamine correlates to memory and attention in Parkinson's disease[J]. Am J Nucl Med Mol Imaging, 2021, 11(1):10-19.
[18]	Patel A, Simon S, et al. Dopamine transporter imaging with Tc-99m TRODAT-1 SPECT in Parkinson's disease and its correlation with clinical disease severity[J]. Asia Ocean J Nucl Med Biol, 2019, 7(1):22-28. doi: 10.22038/AOJNMB.2018.30356.1208 pmid: 30705908
[19]	Gupta V, Ranjan R, Verma R, et al. Correlation of 99m Tc-TRODAT-1 SPECT imaging findings and clinical staging of parkinson disease[J]. Clin Nucl Med, 2019, 44(5):347-350. doi: 10.1097/RLU.0000000000002529 URL
[20]	Pifarre P, Cuberas G, Hernandez J, et al. Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D(2) receptor parkinsonisms[J]. Clin Nucl Med, 2010, 35(4):228-233. doi: 10.1097/RLU.0b013e3181d18cb3 URL
[21]	Hsu SY, Yeh LR, Chen TB, et al. Classification of the multiple stages of Parkinson's disease by a deep convolution neural network based on (99m)Tc-TRODAT-1 SPECT images[J]. Molecules, 2020, 25(20):253-255. doi: 10.3390/molecules25020253 URL
[22]	Howland EJ, Palmer J, Lumley M, et al. Acquired factor Ⅷ inhibitors as a cause of primary post-partum haemorrhage[J]. Eur J Obstet Gynecol Reprod Biol, 2002, 103(1):97-98. pmid: 12039476
[23]	Hossein-Tehrani MR, Ghaedian T, Hooshmandi E, et al. Brain TRODAT-SPECT versus MRI morphometry in distinguishing early mild Parkinson's disease from other extrapyramidal syndromes[J]. J Neuroimaging, 2020, 30(5):683-689. doi: 10.1111/jon.12740 pmid: 32557946
[24]	Evers L, Krijthe JH, Meinders MJ, et al. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS[J]. Mov Disord, 2019, 34(10):1480-1487. doi: 10.1002/mds.27790 URL
[25]	Li DH, Zhang LY, Hu YY, et al. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease[J]. Parkinsonism Relat Disord, 2015, 21(8):923-928. doi: 10.1016/j.parkreldis.2015.05.024 URL
[26]	Wang X, Cao Z, Liu G, et al. Clinical characteristics and electrophysiological biomarkers of Parkinson's disease developed from essential tremor[J]. Front Neurol, 2020, 11:471-474. doi: 10.3389/fneur.2020.00471 URL
[27]	Fallahi B, Esmaeili A, Beiki D, et al. Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders[J]. Ann Nucl Med, 2016, 30(2):153-162. doi: 10.1007/s12149-015-1042-y pmid: 26612262
[28]	Kaasinen V, Vahlberg T, Stoessl AJ, et al. Dopamine receptors in Parkinson's disease: A meta-analysis of imaging studies[J]. Mov Disord, 2021, 36(8):1781-1791. doi: 10.1002/mds.28632 URL
[29]	Kochem A, Orio M, Jarjayes O, et al. Unsymmetrical one-electron oxidized ni(II)-bis(salicylidene) complexes: A protonation-induced shift of the oxidation site[J]. Chem Commun (Camb), 2010, 46(36):6765-6767. doi: 10.1039/c0cc01775b URL
[30]	Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy[J]. J Nucl Med, 2004, 45(1):49-55.
[31]	Tzen KY, Lu CS, Yen TC, et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1[J]. J Nucl Med, 2001, 42(3):408-413. pmid: 11337515

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Jiuxue, Li Na, Jin Wei, Wang Shuo, Chang Yajun, Wang Tianjun. Correlation between serum uric acid, homocysteine and cystatin C levels with motor symptoms and cognitive function in Parkinson's disease patients [J]. Clinical Focus, 2024, 39(2): 125-129.
[2]	. [J]. Clinical Focus, 2023, 38(9): 845-850.
[3]	. [J]. Clinical Focus, 2023, 38(9): 855-858.
[4]	. [J]. Clinical Focus, 2023, 38(2): 189-192.
[5]	Li Wenjun, Zhang Ce, Liu Junyan. Improving circulation aggravates the orthostatic hypotension in a patient with Parkinson's disease: A case report [J]. Clinical Focus, 2022, 37(10): 934-937.
[6]	Guo Chang, Shen Huinan, Sun Yimeng, Wang Dongyu. Correlation between blood lipid and homocysteine and cognitive impairment in Parkinson's disease [J]. Clinical Focus, 2022, 37(2): 128-132.
[7]	Zhao Hang;Ge Hanming;Liang Zhanhua;Wang Yan. Correlation analysis of individualized treatment compliance and disease progression in patients with Parkinson disease [J]. Clinical Focus, 2015, 30(5): 499-502.
[8]	SUN Lin-juan;XU Sheng-li;ZHOU Ming;MAO Li-jun;CHEN Biao. Protection of cysteamine on 1-methy1-4-phenylpyridinium induced SH-SY5Y in Parkinson's disease cell model by antioxidant [J]. Clinical Focus, 2014, 29(7): 740-743.
[9]	SUN Lin-juan;MAO Li-jun;XU Sheng-li;ZHOU Ming;CHEN Biao. Protection of cysteamine on dopaminergic neurons in Parkinson disease mice model by antioxidant [J]. Clinical Focus, 2013, 28(2): 181-0.
[10]	. [J]. Clinical Focus, 2012, 27(15): 1359-0.
[11]	ZENG Wen-jing;ZHANG Xiao-ying;LI Yan-yun;LIU Yan;LI Yan. Relationship between polymorphism of monoamine oxidase B gene and Parkinson disease in Xinjiang Uygurs [J]. Clinical Focus, 2012, 27(9): 764-766.
[12]	. [J]. CLINICAL FOCUS, 2011, 26(10): 888901-0.
[13]	. [J]. CLINICAL FOCUS, 2011, 26(5): 400-0.
[14]	. [J]. CLINICAL FOCUS, 2010, 25(21): 1931-0.
[15]	ZHANG Li;KONG Yan;XU Zhuan;CHEN Jian-hua;ZHANG Zheng-chun. Diagnostic value on pronton magnetic resonance spectroscopy of lentiform nucleus in Parkinson disease [J]. CLINICAL FOCUS, 2009, 24(13): 1115-1117.